Investigational drug · Phase 2
BO-112
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Basal Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "BO-112"
First trial start
2024
May 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BO-112", any sponsor or status.
Conditions studied
As listed on its trial records.
- Basal Cell Carcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BO-112" as an intervention, largest first.
- Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)Active, not recruiting
Highlight TherapeuticsIndustry
NCT06422936 · 50 participants · Start May 27, 2024 · Primary completion Dec 2026
Drug: BO-112 · For: Basal Cell Carcinoma
Sites: Beersheba, Israel; Haifa, Israel; Jerusalem, Israel · 10 sites in all
Highlight TherapeuticsIndustry
NCT02828098 · 44 participants · Start Jun 2016 · Primary completion Jul 2020
Drug: Part 1: BO-112; Part 2: BO-112 · For: Cancer
Sites: Pamplona, Spain; Barcelona, Spain; Madrid, Spain · 7 sites in all
Highlight TherapeuticsIndustry
NCT04570332 · 42 participants · Start Dec 30, 2020 · Primary completion Oct 3, 2023
Drug: BO-112 plus pembrolizumab · For: Melanoma
Sites: Bordeaux, France; Grenoble, France; Lyon, France · 19 sites in all
Clinica Universidad de Navarra, Universidad de NavarraAcademic, hospital or other
NCT05265650 · 30 participants (planned) · Start Jun 13, 2022 · Primary completion Mar 2024
Drug: BO-112 in combination with ablative radiotherapy (SABR) and nivolumab · For: Non-Small Cell Lung Cancer Metastatic
Sites: Pamplona, Spain
- Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver MetastasisTerminated
Highlight TherapeuticsIndustry
NCT04508140 · 18 participants · Start Jun 17, 2020 · Primary completion Dec 2, 2022
Drug: BO-112 with pembrolizumab · For: Colorectal Cancer; Gastric Cancer; Oesophageal Cancer
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 12 sites in all
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT04420975 · 14 participants · Start Oct 14, 2020 · Primary completion Nov 12, 2026
Drug: Nanoplexed Poly I:C BO-112; Nivolumab · For: Leiomyosarcoma; Malignant Peripheral Nerve Sheath Tumor; Myxofibrosarcoma and 27 more
Sites: Los Angeles, California
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT04777708 · 1 participants · Start Oct 13, 2021 · Primary completion Mar 13, 2023
Drug: Nanoplexed Poly I:C BO-112; Pembrolizumab · For: Advanced Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma and 1 more
Sites: Los Angeles, California
Newest research
PubMed records naming it or its code names, newest first.
- Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.
Deng J, Pal A, Testa S, et al. · Cancer Discov 2026
- Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Márquez-Rodas I, Dutriaux C, Saiag P, et al. · J Clin Oncol 2025
- BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Márquez-Rodas I, Dutriaux C, Saiag P, et al. · J Clin Oncol 2025
- Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C.
Gomar C, Di Trani CA, Bella A, et al. · J Immunother Cancer 2024
- Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic.
Alvarez M, Molina C, Garasa S, et al. · Oncoimmunology 2023
- Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.
Rodriguez-Ruiz ME, Serrano-Mendioroz I, Garate-Soraluze E, et al. · J Immunother Cancer 2023
Also in development for Basal Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.